This report was first published by Endpoints News. To see the original version, click here
Genmab has scrapped development of a CD70-targeted antibody-drug conjugate, marking the second clinical-stage asset axed from its $1.8 billion acquisition of ProfoundBio.
The Danish biopharma discontinued development of GEN1160 due to “slow enrollment,” per an update to the US federal trials database last week. The culling is quite fresh: Genmab included GEN1160 in the pipeline portion of its third-quarter report earlier this month.
您已阅读27%（525字），剩余73%（1435字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。